Published in Sci Transl Med on March 05, 2014
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | NCT01740297
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell (2015) 2.60
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. Clin Cancer Res (2015) 1.61
Type I interferons in anticancer immunity. Nat Rev Immunol (2015) 1.57
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A (2015) 1.54
Toward understanding and exploiting tumor heterogeneity. Nat Med (2015) 1.51
Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov (2015) 1.47
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med (2014) 1.44
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov (2016) 1.34
Cancer immunotherapy: the beginning of the end of cancer? BMC Med (2016) 1.32
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol Res (2015) 1.31
Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity. Front Oncol (2014) 1.29
Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
Oncolytic viruses as anticancer vaccines. Front Oncol (2014) 1.13
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol (2015) 1.12
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06
Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Mol Ther (2015) 1.06
NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer (2015) 1.04
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology (2015) 1.02
Oncolytic viruses: From bench to bedside with a focus on safety. Hum Vaccin Immunother (2015) 1.01
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. Mol Ther (2015) 0.97
Oncolysis by paramyxoviruses: preclinical and clinical studies. Mol Ther Oncolytics (2015) 0.95
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency. Mol Ther Oncolytics (2015) 0.94
Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia. Blood (2015) 0.93
Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses. Front Oncol (2014) 0.93
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J Immunother Cancer (2016) 0.89
Tumor localized secretion of soluble PD1 enhances oncolytic virotherapy. Cancer Res (2017) 0.85
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade. Viruses (2016) 0.85
Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy. Oncolytic Virother (2015) 0.84
Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology (2014) 0.84
Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma. Viruses (2015) 0.84
Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy (2015) 0.83
Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. Oncotarget (2015) 0.83
Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol (2015) 0.83
Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies. Front Oncol (2014) 0.83
Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data. Hum Gene Ther (2015) 0.83
The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy. Cancer Gene Ther (2015) 0.83
First oncolytic virus edges towards approval in surprise vote. Nat Biotechnol (2015) 0.83
Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy. Am J Cancer Res (2015) 0.82
Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy. Mol Ther (2017) 0.82
New insights into the mechanism of action of immune checkpoint antibodies. Oncoimmunology (2014) 0.82
Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land. Cancer Gene Ther (2014) 0.82
Oncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpoints. Curr Opin Virol (2015) 0.82
Engineering opportunities in cancer immunotherapy. Proc Natl Acad Sci U S A (2015) 0.82
How to train your oncolytic virus: the immunological sequel. Mol Ther (2014) 0.81
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Rev Respir Med (2015) 0.81
Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses (2015) 0.80
The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome. J Transl Med (2015) 0.79
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic Virother (2016) 0.79
Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines (2017) 0.79
Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil". Biomedicines (2017) 0.79
Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Front Immunol (2017) 0.79
Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Sci Immunol (2017) 0.78
Engineering New Approaches to Cancer Vaccines. Cancer Immunol Res (2015) 0.78
Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? Oncoimmunology (2015) 0.78
A critical role for natural killer cells in dendritic cell-based anticancer immunotherapy. Oncoimmunology (2014) 0.78
Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies. Biomedicines (2016) 0.78
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun (2017) 0.78
From Benchtop to Bedside: A Review of Oncolytic Virotherapy. Biomedicines (2016) 0.78
Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy. J Virol (2016) 0.77
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun (2017) 0.77
Viroimmunotherapy for Colorectal Cancer: Clinical Studies. Biomedicines (2017) 0.77
Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate! Biomedicines (2016) 0.77
High-throughput screening to enhance oncolytic virus immunotherapy. Oncolytic Virother (2016) 0.77
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy (2016) 0.77
Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. Mol Ther Oncolytics (2014) 0.77
CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy. EBioMedicine (2016) 0.77
Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World J Gastroenterol (2016) 0.77
Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers. Mol Ther (2016) 0.77
Murine Tumor Models for Oncolytic Rhabdo-Virotherapy. ILAR J (2016) 0.77
Oncolytic viruses: focusing on the tumor microenvironment. Cancer Gene Ther (2015) 0.77
Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma. Oncoimmunology (2014) 0.76
Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models. Mol Cancer Ther (2015) 0.76
Oncolytic virotherapy for urological cancers. Nat Rev Urol (2016) 0.76
Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment. Sci Rep (2016) 0.76
Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 0.76
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med (2016) 0.76
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther (2017) 0.76
Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy. Gene Ther (2016) 0.75
Type I Interferons and Natural Killer Cell Regulation in Cancer. Front Immunol (2017) 0.75
Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncolytic Virother (2015) 0.75
Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy. Viruses (2016) 0.75
Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity. J Immunol (2016) 0.75
Combined genetic and epigenetic interferences with interferon signaling expose prostate cancer cells to viral infection. Oncotarget (2016) 0.75
Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy. Front Oncol (2017) 0.75
Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis. Mol Ther Oncolytics (2017) 0.75
Proinflammatory response induced by Newcastle disease virus in tumor and normal cells. Oncolytic Virother (2017) 0.75
Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses. Hum Gene Ther (2014) 0.75
What does the future hold for immunotherapy in cancer? Ann Transl Med (2016) 0.75
Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer. Front Oncol (2017) 0.75
Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy. Front Oncol (2017) 0.75
Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines. Curr Opin Immunol (2017) 0.75
Immune System, Friend or Foe of Oncolytic Virotherapy? Front Oncol (2017) 0.75
Oncolytic measles virus enhances antitumour responses of adoptive CD8(+)NKG2D(+) cells in hepatocellular carcinoma treatment. Sci Rep (2017) 0.75
Shifting the balance of power? The combination of oncolytic virotherapy and immune checkpoint blockade for glioblastoma treatment. Neuro Oncol (2017) 0.75
Fighting Cancer with Mathematics and Viruses. Viruses (2017) 0.75
Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Cell type-specific involvement of RIG-I in antiviral response. Immunity (2005) 9.37
Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 6.81
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 4.77
Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature (2011) 4.61
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02
An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother (2011) 4.02
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J (2010) 3.99
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85
Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res (1975) 3.59
IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol (2010) 3.43
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol (2010) 2.65
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol (2002) 2.41
Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol (2007) 1.84
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res (2001) 1.66
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol (2012) 1.52
IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest (2011) 1.46
Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res (2012) 1.28
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol (2012) 1.28
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol (2009) 1.28
Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther (2009) 1.18
Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol Biol (2009) 1.17
Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Int J Oncol (2009) 1.08
T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. Trends Mol Med (2003) 1.08
Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. J Virol (2010) 1.07
Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Cancer Gene Ther (2008) 0.99
Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Int J Oncol (2011) 0.92
Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNgamma primed and IFNbeta treated B7-1+ B16-F10 melanoma cells. Immunol Cell Biol (2003) 0.84
Role of interferon in the anti-melanoma effects of poly (I).poly (C) and Newcastle disease virus. Nat New Biol (1973) 0.81
Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization. Proc Natl Acad Sci U S A (2017) 0.75